Allworth Financial’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.1K Buy
402
+301
+298% +$8.19K ﹤0.01% 4060
2026
Q2
$2.72K Sell
101
-253
-71% -$6.94K ﹤0.01% 4386
2026
Q1
$9.6K Buy
354
+135
+62% +$3.96K ﹤0.01% 3539
2025
Q4
$7.95K Buy
219
+175
+398% +$7.02K ﹤0.01% 3422
2025
Q3
$1.67K Buy
44
+10
+29% +$216 ﹤0.01% 4085
2025
Q2
$461 Sell
34
-56
-62% -$811 ﹤0.01% 4158
2025
Q1
$1.27K Buy
90
+62
+221% +$713 ﹤0.01% 3383
2024
Q4
$286 Sell
28
-105
-79% -$1.37K ﹤0.01% 3722
2024
Q3
$1.61K Hold
133
– – ﹤0.01% 3048
2024
Q2
$1.76K Buy
+133
New +$1.68K ﹤0.01% 2980

Other funds holding MLYS

Allworth Financial's MLYS Position: Q3 2026 in Review

Allworth Financial increased its Mineralys Therapeutics (MLYS) stake by 298% in Q3 2026, buying an estimated $8.19K and bringing the position to 402 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4060.

Allworth Financial first reported a position in MLYS in Q2 2024 and has held it in 10 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Allworth Financial held 402 shares of Mineralys Therapeutics worth $10.1K as of Q3 2026.
  • Allworth Financial bought 301 Mineralys Therapeutics shares in Q3 2026, an estimated $8.19K.
  • Mineralys Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q3 2026, its #4060 holding.
  • Allworth Financial first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Allworth Financial's 13F filing for Q3 2026, filed 6 Nov 2026.